Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Reinhard DummerGeorgina V LongCaroline RobertHussein A TawbiKeith T FlahertyPaolo Antonio AsciertoPaul D NathanPiotr Lukasz RutkowskiOleg LeonovCaroline DutriauxMario MandalaPaul C LoriganPier Francesco FerrucciJean-Jacques GrobNicolas MeyerHelen J GogasDaniil StroyakovskiyAna M AranceJan C BraseSteven GreenTomas HaasAisha MasoodEduard GasalAntoni RibasDirk SchadendorfPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.